Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo

AbbVie's experimental drug ABBV-466, combining Skyrizi with trosunilimab, showed promising Phase 2 results for Crohn's disease, nearly doubling remission rates compared to either drug alone. Analysts view it as a potential blockbuster follow-up to Skyrizi, though Phase 3 trials and regulatory approval still lie ahead. The company's strong track record in lifecycle management supports investor confidence.